Advertisements

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA®

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA®.....»»

Category: press-releasesSource: businesswireindiaJun 14th, 2017

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®.....»»

Category: press-releasesSource: businesswireindiaJul 28th, 2017

Cyltezo®, adalimumab biosimilar from Boehringer Ingelheim, approved in Europe for the treatment of multiple chronic inflammatory diseases

Cyltezo®, adalimumab biosimilar from Boehringer Ingelheim, approved in Europe for the treatment of multiple chronic inflammatory diseases.....»»

Category: press-releasesSource: businesswireindiaNov 13th, 2017

Boehringer Ingelheim receives positive CHMP opinion for adalimumab biosimilar CYLTEZO®

Boehringer Ingelheim receives positive CHMP opinion for adalimumab biosimilar CYLTEZO®.....»»

Category: press-releasesSource: businesswireindiaSep 16th, 2017

Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH

Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH.....»»

Category: press-releasesSource: businesswireindiaAug 24th, 2017

Final Phase III Study Results Confirm Benefit of Praxbind® as Reversal Agent for Pradaxa® Patients in Emergency Situations

Final Phase III Study Results Confirm Benefit of Praxbind® as Reversal Agent for Pradaxa® Patients in Emergency Situations.....»»

Category: press-releasesSource: businesswireindiaJul 12th, 2017

Lupin JV announces outcome of Phase III study for biosimilar, Etanercept

Lupin JV announces outcome of Phase III study for biosimilar, Etanercept.....»»

Category: topSource: moneycontrolFeb 7th, 2018

Lupin JV announces outcome of Phase III study for biosimilar, Etanercept

Lupin JV announces outcome of Phase III study for biosimilar, Etanercept.....»»

Category: topSource: moneycontrolFeb 7th, 2018

Glenmark Pharma presents preliminary biomarker data on GBR 1302

Glenmark Pharma presents preliminary biomarker data on GBR 1302.....»»

Category: topSource: moneycontrolJan 24th, 2018

Glenmark Pharma announces results from phase 3 safety study evaluating Ryaltris

Glenmark Pharma announces results from phase 3 safety study evaluating Ryaltris.....»»

Category: topSource: moneycontrolDec 13th, 2017

Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® (dabigatran etexilate) dual therapy was used instead of warfarin triple therapy

Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® (dabigatran etexilate) dual therapy was used instead of warfarin triple therapy.....»»

Category: press-releasesSource: businesswireindiaNov 16th, 2017

Takeda Presents Updated Results from Pivotal Phase 2 ALTA Trial of ALUNBRIG™ (brigatinib) in ALK-Positive Non-Small Cell Lung Cancer

Takeda Presents Updated Results from Pivotal Phase 2 ALTA Trial of ALUNBRIG™ (brigatinib) in ALK-Positive Non-Small Cell Lung Cancer.....»»

Category: press-releasesSource: businesswireindiaOct 16th, 2017

Glenmark’s dermatitis molecule displays positive results in phase-2a trial

Glenmark’s dermatitis molecule displays positive results in phase-2a trial.....»»

Category: featuresSource: livemintAug 1st, 2017

Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma

Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma.....»»

Category: press-releasesSource: businesswireindiaJun 27th, 2017

Encouraging Phase II survival data for nintedanib in malignant pleural mesothelioma presented at ASCO 2017

Encouraging Phase II survival data for nintedanib in malignant pleural mesothelioma presented at ASCO 2017.....»»

Category: press-releasesSource: businesswireindiaJun 5th, 2017

PMI’s Latest Clinical Results: Findings Add to Extensive Evidence Package on Risk Reduction

PMI’s Latest Clinical Results: Findings Add to Extensive Evidence Package on Risk Reduction.....»»

Category: press-releasesSource: businesswireindiaJun 18th, 2018

Kemwell Biopharma Selected to Manufacture the Monoclonal Antibody Drug Substance For a US Phase 3 Clinical Trial

Kemwell Biopharma Selected to Manufacture the Monoclonal Antibody Drug Substance For a US Phase 3 Clinical Trial.....»»

Category: press-releasesSource: prnewswireJun 5th, 2018

Results of Phase III RELEVANCE Study Comparing REVLIMID plus Rituximab (R2) Versus Rituximab Plus Chemotherapy in Patients with Previously Untreated Follicular Lymphoma to be Presented at ASCO 2018

Results of Phase III RELEVANCE Study Comparing REVLIMID plus Rituximab (R2) Versus Rituximab Plus Chemotherapy in Patients with Previously Untreated Follicular Lymphoma to be Presented at ASCO 2018.....»»

Category: press-releasesSource: businesswireindiaJun 4th, 2018

Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma

Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma.....»»

Category: press-releasesSource: businesswireindiaJun 2nd, 2018

Deshhit: By-poll results has set the stage for 2019 general elections - Zee News

Deshhit: By-poll results has set the stage for 2019 general elections - Zee News.....»»

Category: topSource: googlenewsJun 1st, 2018

In this era of personalised medicine, are big clinical trials relevant?

In this era of personalised medicine, are big clinical trials relevant?.....»»

Category: economySource: business-standardMay 30th, 2018